STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Rasonque generated $198 million in sales during its first five weeks following U.S. approval, delivering an exceptionally fast commercial start for the pancreatic cancer drug.
- Revolution Medicines said more than 5,000 patients had already been treated with Rasonque by Wednesday evening.
- Rasonque posted sales nearly double even the most bullish investor estimates ahead of Revolution Medicines’ third-quarter earnings announcement.
- Anthony Mancini, Revolution Medicines’ chief commercial officer, described the U.S. launch as “off to a strong start” on the company’s earnings call.
- Rasonque was already close to the best cancer-drug launch in history, though the five-week sales window was too early to establish a definitive record.
Why it matters: Investors’ revenue expectations for Revolution Medicines were overtaken by Rasonque’s $198 million five-week haul, nearly double even the most bullish estimate. With more than 5,000 patients treated, the pancreatic cancer launch has established a larger commercial baseline than investors anticipated.
Ask SkimNews
